Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market
TheFly reported on February 6 that Piper Sandler raised its price target on TVTX to $38 from $35 and maintained a Neutral rating on the shares.
Travere Therapeutics Inc. (TVTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 4,278,180 | $163,469,258 | +13% | 2.91% |
| 2. | Armistice Capital Steven Boyd | 3,763,891 | $143,818,275 | -45% | 1.71% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 2,927,000 | $111,840,670 | -18% | 0.17% |
| 4. | Renaissance Technologies Jim Simons | 2,246,779 | $85,849,426 | +29% | 0.13% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 2,210,322 | $84,456,404 | +3% | 4.33% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | $89,250.00 | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | $76,564.50 | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | $129,049.50 | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | $51,118.00 | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | $73,950.00 | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.85 | 232 | $7,621.20 | 105,706 | 2026-02-04 | Filing | |
| $32.11 | 1,547 | $49,674.17 | 105,938 | 2026-02-04 | Filing | |
| $32.90 | 110 | $3,619.00 | 111,226 | 2026-02-04 | Filing | |
| $32.14 | 1,635 | $52,548.90 | 111,336 | 2026-02-04 | Filing | |
| $32.74 | 509 | $16,664.66 | 105,211 | 2026-02-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,511,166 | $401,715,922 | 0.18% | |
| 2. | 9,617,863 | $367,498,538 | 0.02% | |
| 3. | 7,869,352 | $300,687,941 | 0.01% | |
| 4. | 6,309,229 | $241,075,642 | 0% | |
| 5. | 4,756,666 | $181,752,208 | 0.01% |
News See All
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings
Travere Therapeutics soared by 25.3 percent week-on-week as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong note...
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook
Travere Therapeutics climbed to a fresh record high on Friday, as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong...
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Travere Therapeutics' Third Quarter 2025 Financial Results Conference Call. Today's call is being recorded.
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside
Travere Therapeutics, Inc.
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best small cap stocks with biggest upside potential.
9 Best Small Cap Stocks with Biggest Upside Potential
On August 14, Jonathan Krinsky of BTIG, joined 'Closing Bell' on CNBC to discuss whether the recent rally in small cap stocks is sustainable.
Hedge Fund Resource Center Billionaire Hedge Funds
